{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045807","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.627310+00:00","generated_at":"2026-05-30T04:18:35.339879+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cumberland announces study showing Caldolor reduces adverse drug reactions vs ketorolac","bullets":["Study analyzed records of >17M patients; compared 31,046 Caldolor vs 124,184 ketorolac adults.","Caldolor associated with 45% reduction in renal dysfunction (p<0.001) and 78% fewer hematuria events.","In pediatric patients, Caldolor showed 51-65% lower rate of adverse drug reactions.","Caldolor also linked to decreased ER visits and shorter hospital stay for both adults and children."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045807","json":"https://secwatch.observer/filing/0001628280-24-045807.json","markdown":"https://secwatch.observer/filing/0001628280-24-045807.md","text":"https://secwatch.observer/filing/0001628280-24-045807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024045807/0001628280-24-045807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828024045807/cpix-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:18:35.339879+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}